Closer to Free Funds Lifesaving Clinical Trial for Smilow Patient
Christopher Brewster is six months into remission from lymphoma. It’s the longest remission he’s had so far. He also likes that 100% of the money raised from Closer to Free goes to support programs like clinical trials that potentially save lives.Source: NBC Connecticut
Bold Plans for Cancer Care at Yale
Eric Winer, MD, began his tenure at Yale in February 2022 with a vision to expand the cancer program and national prominence of Yale Cancer Center and Smilow Cancer Hospital. He is already recruiting more physicians and researchers and focusing on healthcare inequities in Connecticut.
Video: 'Exciting Time' for Bladder Cancer Treatment
In this exclusive video, Daniel Petrylak, MD, co-director of the Signal Transduction Program at Yale University Cancer Center in New Haven, Connecticut, discusses data presented at the ASCO annual meeting on enfortumab and how it will improve bladder cancer patient outcomes.Source: Medpage Today
Defining the Landscape of Prostate Cancer Treatment
Through the expertise of Isaac Kim, MD, PhD, MBA, Professor and Chair of Urology, new robotic technology at Smilow Cancer Hospital reduces the number of incisions for prostatectomies from six to two. As a result, men with prostate cancer are benefiting from a reduction in complications, pain, and hospital stays.
Opioids and Cancer: How to Prevent and Manage Misuse
Since 1999, the opioid epidemic has claimed the lives of more than half a million people in the United States. Laws have been passed to limit the public’s access to opioids, but these laws may inadvertently affect patients who rely on prescription opioids to manage pain, particularly patients with cancer.Source: Cancer Therapy Advisor
Treating the Whole Patient
Smilow Cancer Hospital’s new Psycho-Oncology Program draws on best practices from across the country and within Smilow to provide psychotherapy counseling and support for patients experiencing challenges such as depression, anxiety, insomnia, and fatigue while undergoing cancer treatment.
Top Takeaways in Lung Cancer From ASCO 2022
share to facebook share to twitter share to linkedin email article Play VideoPlay Mute Remaining Time -4:25 CaptionsFullscreen The American Society of Clinical Oncology (ASCO) annual meeting is the stage for presenting many of the most impactful advancements in cancer research -- including in lung cancer. In this second of four exclusive episodes, MedPage Today brought together three leaders in the field -- moderator Roy S. Herbst, MD, PhD, of Yale Cancer Center in New Haven, Connecticut, is joined by Jorge Nieva, MD, of the Keck School of Medicine of USC in Los Angeles, and Sarah Goldberg, MD, also of Yale Cancer Center -- for a roundtable discussion reviewing the most influential lung cancer research presented during the meeting and providing insights on how the new data will influence clinical practice.Source: Medpage Today
Understanding Poor Vaccine Responses in Individuals With Weakened Immune Systems
Yale researchers have received a $12 million award from the NIH as part of the Human Immune Project Consortium to study vaccine responses in vulnerable groups, including patients with multiple sclerosis (MS) undergoing B cell depletion therapy, older adults including particularly vulnerable older residents of long-term care facilities, and certain individuals with sickle cell disease.